preloader

Writing

illustrations

illustrations

illustrations

illustrations

illustrations

illustrations

illustrations

All Analyst insight Journal article Conference review Press release

Xeljanz safety data in RA could mean headaches for all JAK inhibitors

Xeljanz safety data in RA could mean headaches for all JAK inhibitors

Subcutaneous Infliximab In The U.S.: Defining CT-P13 SC's Competitive Edge

Subcutaneous Infliximab In The U.S.: Defining CT-P13 SC's Competitive Edge

MANTA and MANTA-RAy Safety Readouts Boost Jyseleca’s Prospects in the US

MANTA and MANTA-RAy Safety Readouts Boost Jyseleca’s Prospects in the US

Subcutaneous Infliximab In The U.S.: Assessing CT-P13 SC's Impact Across Indications

Subcutaneous Infliximab In The U.S.: Assessing CT-P13 SC's Impact Across Indications

Weighing The Potential Of Humira Biosimilars In The U.S.: Expected Winners And Losers

Weighing The Potential Of Humira Biosimilars In The U.S.: Expected Winners And Losers

Weighing The Potential Of Humira Biosimilars In The U.S.: Competitive Dynamics Analysis

Weighing The Potential Of Humira Biosimilars In The U.S.: Competitive Dynamics Analysis

MARKET BRIEF – Allergic Rhinitis Immunotherapy: Opportunity Analysis & Forecasts to 2028

MARKET BRIEF – Allergic Rhinitis Immunotherapy: Opportunity Analysis & Forecasts to 2028

Early phase II data cuts suggest Aprea’s APR-246 will be a game-changer for TP53 mutant MDS

Early phase II data cuts suggest Aprea’s APR-246 will be a game-changer for TP53 mutant MDS

Treatment with some JAK inhibitors linked to increased risk of shingles

Treatment with some JAK inhibitors linked to increased risk of shingles

URGENT/11 vulnerabilities showcase cybersecurity risks for connected medical devices

URGENT/11 vulnerabilities showcase cybersecurity risks for connected medical devices

ICER provides vote of confidence to AbbVie’s Rinvoq as it makes substantial leap in cost-effectiveness, says GlobalData

ICER provides vote of confidence to AbbVie’s Rinvoq as it makes substantial leap in cost-effectiveness, says GlobalData

Despite resubmission of Viaskin Peanut BLA, AR-101’s likely first-to-market advantage could still setback DBV Technologies

Despite resubmission of Viaskin Peanut BLA, AR-101’s likely first-to-market advantage could still setback DBV Technologies

Allakos’ success: first big step into GI space

Allakos’ success: first big step into GI space

Excellent phase 3 trial data for rheumatoid arthritis drug filgotinib – but long road ahead

Excellent phase 3 trial data for rheumatoid arthritis drug filgotinib – but long road ahead

Phase III failure for Pollinex Quattro Birch puts Allergy Therapeutics in a precarious position for long-awaited US expansion, says GlobalData

Phase III failure for Pollinex Quattro Birch puts Allergy Therapeutics in a precarious position for long-awaited US expansion, says GlobalData

Why are children more resistant to mortality from severe infections?

Why are children more resistant to mortality from severe infections?

RISE registry captures key trends in RA treatment

RISE registry captures key trends in RA treatment

Could upadacitinib upend the US JAK inhibitor market?

Could upadacitinib upend the US JAK inhibitor market?

Prescriber preferences are blocking biosimilar uptake in RA

Prescriber preferences are blocking biosimilar uptake in RA

How will the generics giants shape the epinephrine injection market?

How will the generics giants shape the epinephrine injection market?

Epinephrine auto-injectors: to prescribe or not to prescribe

Epinephrine auto-injectors: to prescribe or not to prescribe

The relative resistance of children to sepsis mortality: from pathways to drug candidates

The relative resistance of children to sepsis mortality: from pathways to drug candidates

Nima Peanut Sensor aims to take a bite out of patients’ anxiety

Nima Peanut Sensor aims to take a bite out of patients’ anxiety

Characterising Pre-pubertal Resistance to Death from Endotoxemia

Characterising Pre-pubertal Resistance to Death from Endotoxemia